What are biotech investors thinking?

October 13, 2020
BIO Investor Forum Digital begins today—and we give you a sneak peek at what you’ll hear from both investors and emerging companies, as well as tell you how to follow along. We also take a closer look at COVID-19 and the world’s plastic problem and what’s happening in…
BIO

BIO Investor Forum Digital begins today—and we give you a sneak peek at what you’ll hear from both investors and emerging companies, as well as tell you how to follow along. We also take a closer look at COVID-19 and the world’s plastic problem and what’s happening in Washington. Here are around 785 words, just under 4 minutes.

 

Sponsored content by ICON 

ICON logo
ICON offers a flexible partnership model for biotechs, acting as a fully externalised project development team, starting in the preclinical phase to clinical research to real world studies through to commercialisation. We assist biotechnology companies with portfolio prioritisation and technical and commercial evaluation of out- or in-licensed assets, across all therapeutic areas, including Cell and Gene Therapies. Learn more
 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
 

How to follow BIO Investor Forum Digital

  • Head to the BIO Investor Forum Digital Live Blog (www.bio.org/bif/live), where our team of writers is bringing you the highlights, live and in real time as its happening.
  • Join the conversation at @IAmBiotech with #BIFDigital.
  • Did we give you FOMO? It’s not too late to register for full access (including BIO One-on-One Partnering) or the education pass, which includes access to educational sessions, company presentations, and video networking. 

What we’re watching today: The event begins with an update on COVID-19 and policy (10:45 AM ET/7:45 AM PT), with BIO President and CEO Dr. Michelle McMurry-Heath and BIO Chair Dr. Jeremy Levin, moderated by The Hill’s Editor-at-Large Steve Clemons. Immediately after, we’ll discuss how to address disparities in therapeutic development (11:30 AM ET/8:30 AM PT) and hear what’s new with the AMR Action Fund (12:30 PM ET/9:30 AM PT). In the afternoon, get expert insights on how to manage teams during a pandemic (2:00 PM ET/11:00 AM PT). To finish the day, Dave Thomas, BIO’s VP of Industry Analysis, will look at VC investment in emerging therapeutic companies (5:00 PM ET/2:00 PM PT).

 
Twitter
 
LinkedIn
 
Facebook
 

What are biotech investors thinking?

 
 

The world is seeing an unprecedented response to the COVID-19 pandemic by biotech researchers and companies of all sizes. This week, get inside the minds of biotech investors (and emerging companies) to learn what’s ahead for the industry and how we can bring the next generation of vaccines, therapeutics, and diagnostics to patients. 

We’re seeing an unprecedented response to COVID-19. By the latest count on the BIO COVID-19 Therapeutic Development Tracker, there are 742 unique active compounds in the COVID-19 pipeline, including 190 vaccines.

But it’s not just about COVID. Of the 20 emerging therapeutic companies receiving the most venture capital, 50% are in the oncology space, according to BIO’s VP of Industry Analysis Dave Thomas. (He’ll talk about this more later today!

Why does investment matter? “Biotech is a very capital-intensive business,” said Brad Loncar, CEO of Loncar Investments. It’s risky and requires a lot of investment to get through different stages of development, like clinical trials and regulatory approvals.

What do investors look for? “Transformative, proprietary science or technology that has the potential to disrupt an existing big market or create a new market with significant unmet needs,” explained Dr. Alexis Ji, Partner at Illumina Ventures.

Watch:
 
Preview: Biotech Investment in 2020
 

Want to get inside an investor’s mind? Listen to the latest episode of the I AM BIO Podcast, featuring Deerfield’s Alex Karnal in conversation with BIO’s Dr. Michelle McMurry-Heath.

Are you new here? Welcome to Good Day BIO, the only newsletter at the intersection of biotech, politics, and policy. Visit the archives to catch up on past issues and subscribe.

 

More Health Care News: 

STAT News: Johnson & Johnson COVID-19 vaccine study paused due to unexplained illness in participant
“Though clinical trial pauses are not uncommon—and in some cases last only a few days—they are generating outsized attention in the race to test vaccines against SARS-CoV-2.”

The New York Times: The race for a super-antibody against the coronavirus
"A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans."

 
Twitter
 
LinkedIn
 
Facebook
 

Another pandemic: plastic pollution

 
 

Plastic helps reduce contact with COVID-19 and keep health care and other essential workers safe in the form of face shields, hospital gowns, gloves, and takeout containers, reports Reuters. But it’s also intensifying the world’s plastic problem. What’s the solution?

COVID-19 has made the world’s plastic problem even worse. Plastic already makes up 80% of ocean debris, kills marine animals, and releases chemicals that can harm humans.

Meanwhile, with oil prices low, new plastic is cheaper than recycled plastic—increasing demand for it. As a result, the fossil fuel industry plans to invest $400 billion over the next five years on plants to make raw materials for virgin plastic,” continues Reuters.  

But: “Even if existing recycling pledges are met, the plastic going into the oceans is on course to rise from 11 million tonnes now to 29 million by 2040, according to a study published in June by Pew Trusts,” explains the report. “Cumulatively, this would reach 600 million tonnes – the weight of 3 million blue whales.” 

This is why we need sustainable alternatives like bioplastics made from renewable feedstocks, which are versatile and durable—and in some cases look and feel just like fossil fuel-based plastics—but are also recyclable and biodegradable.

As we think about building back from COVID-19, let’s think about supporting the bioeconomy—which can create jobs and economic growth while providing a solution to help clean up the environment and reduce our impact on animal and human health.  

 

More Agriculture and Environment: 

Twist Bioscience: Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies
“The companies will leverage Neogene’s proprietary expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, together with Twist’s DNA synthesis platform and product lines to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.”

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook
 
BIO Beltway Report
GoodDayBIO
 
 

President Trump’s Tuesday: Heading to Johnstown, PA, for a campaign rally, after his doctor said he tested negative for COVID-19 “on consecutive days.” Later this week, he’s scheduled to campaign in Iowa, where COVID-19 is “out of control,” reports STAT News

What’s Happening on Capitol Hill: The Senate Judiciary Committee’s hearing on Supreme Court nominee Judge Amy Coney Barrett continues today. RIP Roberta McCain.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook